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Abstract
Background: Depressive symptoms are usually managed within primary care and antidepressant medication
constitutes the first-line treatment. It remains unclear at present which people are more likely to benefit from
antidepressant medication. This paper describes the protocol for a randomised controlled trial (PANDA) to
investigate the severity and duration of depressive symptoms that are associated with a clinically significant
response to sertraline compared to placebo, in people presenting to primary care with depression.
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Methods/design: PANDA is a randomised, double blind, placebo controlled trial in which participants are
individually randomised to sertraline or placebo. Eligible participants are those who are between the ages
of 18 to 74; have presented to primary care with depression or low mood during the past 2 years; have not
received antidepressant or anti-anxiety medication in the 8 weeks prior to enrolment in the trial and there
is clinical equipoise about the benefits of selective serotonin reuptake inhibitor (SSRI) medication. Participants
who consent to participate in the trial are randomised to receive either sertraline or matching placebo, starting at 50
mg daily for 1 week, increasing to 100 mg daily for up to 11 weeks (with the option of increasing to 150
mg if required). Participants, general practitioners (GPs) and the research team will be blind to treatment
allocation. The primary outcome will be depressive symptoms measured by the Patient Health Questionnaire-9
(PHQ-9) at 6 weeks post randomisation, measured as a continuous outcome. Secondary outcomes include
depressive symptoms measured with the PHQ-9 at 2 and 12 weeks as a continuous outcome and at 2, 6 and
12 weeks as a binary outcome; follow-up scores on depressive symptoms measured with the Beck Depression
Inventory-II, anxiety symptoms measured by the Generalized Anxiety Disorder-7 and quality of life measured
with the Euroqol-5D-5L and Short Form-12; emotional processing task scores measured at baseline, 2 and 6
weeks; and costs associated with healthcare use, time off work and personal costs.
Discussion: The PANDA trial uses a simple self-administered measure to establish the severity and duration of
depressive symptoms associated with a clinically significant response to sertraline. The evidence from the trial
will inform primary care prescribing practice by identifying which patients are more likely to benefit from
antidepressants.
Trial registration: Controlled Trials ISRCTN Registry, ISRCTN84544741. Registered on 20 March 2014. EudraCT
Number: 2013-003440-22; Protocol Number: 13/0413 (version 6.1).
Keywords: Depression, Primary care, Antidepressants, Sertraline, Selective Serotonin reuptake inhibitors
Background
Depression is a common condition that affects be-
tween 9% and 12% of the population at any one time
[1] and is linked to higher rates of functional disabil-
ity compared with most chronic medical illnesses [2].
Recent estimates suggest that depression is the lead-
ing cause of disability in high and middle-income
countries [3, 4]. Depressive symptoms are usually
managed within primary care and antidepressant
medication is often the first line of treatment [5].
Overall, around 80% of people presenting with de-
pression in UK general practice receive antidepres-
sants [5, 6].
A dramatic rise of antidepressant medication pre-
scription has been observed in recent years. There was
an increase of 7.2% between 2013 and 2014 [7], and in
2014 over 57 million antidepressant prescriptions were
issued in England, at a cost of £265 million [8]. Similar
increases in antidepressant consumption have been ob-
served in other high-income countries. [9]. Studies in
UK primary care linked databases have found that the
rate of new prescribing over this period remained stable
and the increase in numbers of prescriptions arose be-
cause of an increase in the average duration of treat-
ment with selective serotonin re-uptake inhibitors
(SSRIs) [10, 11]. Given that individuals who receive
antidepressant medication are likely to do so for long
periods, there is a need to identify those individuals
who are more likely to derive a clinical benefit from
antidepressants.
One hypothesis to guide prescription is that the re-
sponse to antidepressants (compared to placebo) is
greater in those with more severe illness. Results from
systematic reviews of aggregate data and from individual
patient data have provided inconsistent support for this
hypothesis [12–15]. One possible reason is that some
studies had a narrow range of baseline severity. This will
reduce the power to detect an interaction between base-
line severity and response even in large databases. A dif-
ferent approach towards this question has been to
restrict trials to people with “minor” depression not
meeting the usual diagnostic criteria. A systematic re-
view of studies of “minor” depression found no evidence
for a beneficial treatment effect of antidepressants [16]
consistent with the idea that there must be a lower
threshold below which antidepressants are not effective.
Given this conflicting evidence, we wish to test the hy-
pothesis that the baseline severity of depression is likely
to be a factor that can be used to predict benefit from
antidepressant treatment.
The other possible factor that might be useful to pre-
dict response is the duration of depressive symptoms.
Evidence suggests that antidepressants are effective in
people with dysthymia [17] even though they do not
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meet the criteria for major depression. As a result the
National Institute for Clinical Excellence (NICE) guidelines
recommend SSRIs for “persistent subthreshold depressive
symptoms” but give no definition of persistence [18].
Although general practitioners (GPs) have consider-
able expertise in identifying depression [19, 20], it is
well-known that the measurement of depression is no-
toriously difficult using clinical assessment. This has led
to the development of a whole range of standardised
scales of varying length. Short, self-administered, ques-
tionnaires such as the PHQ-9 [21] are not sufficiently
detailed to assess severity and duration accurately. On
the other hand, semi-structured standardized interviews
designed to assess depressive symptoms and diagnostic
criteria are lengthy and often require the interviewer to
use expert psychiatric judgments, a task that is not feas-
ible in primary care settings [22]. If we are to provide
guidance to GPs about the severity and duration of de-
pression that may respond to treatment with antidepres-
sants then we require a standardised assessment that is
sufficiently detailed but could be used in primary care.
The final area we want to investigate is neuropsycho-
logical markers of antidepressant action. Harmer [23]
and others have found consistently that antidepressants
(both serotonin and noradrenaline drugs) acutely affect
performance on emotion processing tasks, even though
there is no subjective awareness of any change or im-
provement in mood. For example, memory of positive
words is increased within a few days of taking antide-
pressants in healthy volunteers and in those with
depression [24, 25]. The change in emotion-processing
following antidepressant use is the reverse of that seen
in depression and occurs before the onset of any clinical
change in symptoms. Their theory suggests that the
delay between the emotion-processing change and de-
pressive symptoms depends upon the need to experience
new events after the change of emotion processing has
occurred. These markers of antidepressant response
could be a factor that might be useful in predicting likely
response to antidepressants.
Our overall aim is to improve the guidance for GPs
and patients on who will benefit from treatment with
antidepressants. We therefore propose to carry out a
randomised controlled trial (RCT) to investigate the se-
verity and duration of depressive symptoms that are as-
sociated with a clinically important response to
sertraline in people presenting to primary care with de-
pression. We plan to assess severity and duration of de-
pression using a standardised measure (the Revised
Clinical Interview Schedule (CISR) [22]) that can be self-
administered on a computer and completed by the pa-
tient outside the consultation with the physician, so
could potentially be used to guide assessment and pre-
scription in primary care [26, 27]. Additionally, we want
to investigate the effects of antidepressants on measures
of emotion processing that might mediate the thera-
peutic effects and could also be a potential measure for
predicting antidepressant response.
Our specific aims are:
1. To investigate the severity and duration of the
depressive symptoms that are associated with a
clinically important response to sertraline
(compared to placebo) in people with depression
2. To investigate quality of life and the economic costs
associated with response to treatment with sertraline
3. To test the hypothesis that sertraline will lead to an
early change in emotion processing that will mediate
any treatment effect on depressive symptoms
The long-term benefits of the trial will be in improving
guidance/treatment recommendations for primary-care
clinicians, thereby increasing the likelihood that a pre-
scription will lead to clinical benefit, while reducing pre-
scriptions that are not needed. We will include adult
patients presenting in primary care with depressive
symptoms/low mood, who are not currently on antide-
pressants (or in the previous 8 weeks) and the GP and/
or patient are unsure whether there will be significant
clinical benefit from taking SSRI antidepressants.
Methods/design
Study design
PANDA is a randomised, double-blind, placebo-controlled
study in which eligible participants are individually rando-
mised to sertraline or placebo. The sertraline will be encap-
sulated and matching placebo capsules will be produced in
order to maintain the blind allocation during the study.
Participants will be recruited from primary care practices
across the UK in the areas surrounding our four trial sites:
Bristol, London, Liverpool and York.
Trial treatment will be for 12 weeks with research
follow-up assessments at 2, 6 and 12 weeks (see Fig. 1
for a summary of the baseline and follow-up assessment
schedule). The PHQ-9 [21] was selected as the primary
outcome for depressive symptoms to avoid the observer
bias associated with clinician-rated measures. The main
treatment response of sertraline compared with placebo
occurs within about 6 weeks, so in line with most anti-
depressant trials our primary outcome will be measured
at the 6-week follow up. We also want to obtain an early
assessment of adverse events, emotion processing and
clinical response at 2 weeks as the first signs of improve-
ment can occur at that point [28]. The 12-week assess-
ment will provide evidence of any sustained benefit. In
order to test our hypothesis about emotion processing
and antidepressants [23], we will use two emotional pro-
cessing tasks looking at (1) the recall of socially rewarding
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information and (2) reinforcement learning of reward and
punishment (related to monetary rewards) that will be ad-
ministered at baseline and then early on after 2 weeks, be-
fore we expect to see any clinical response.
Sertraline is an SSRI that is licensed for the treatment
of depression and has a well-established efficacy profile.
A recent network meta-analysis suggested that, if any-
thing, it was more efficacious and better tolerated than
most of the other SSRIs [29]. As a result it is one of the
recommended SSRIs to use as a first choice in the treat-
ment of depression [18] and is very widely prescribed in
primary and secondary care in the UK and elsewhere in
the world.
We want to keep the inclusion criteria pragmatic and
broad to reflect the current dilemma in clinical practice,
so uncertainty of GP and/or patient about the possible
benefits of antidepressants is the key entry criterion for
the trial. We will not impose any additional criteria of
severity and duration ourselves.
Inclusion and exclusion criteria
Inclusion criteria
People will be eligible for inclusion if they are between
18 and 74 years (inclusive) of age; have presented to
primary care in the UK with depression at any point in
the previous 2 years; and if there is clinical equipoise
about the benefits of SSRI medication.
Exclusion criteria
People will be excluded if they have received antidepres-
sant medication in the preceding 8 weeks; are unable to
read, understand and/or complete questionnaires; suffer
from other psychiatric disorders (i.e. psychosis, schizo-
phrenia, bipolar disorder, mania, hypomania, dementia,
eating disorder); suffer from major alcohol or substance
abuse problems; are currently on contraindicated medi-
cation (i.e. monoamine oxidase inhibitors within the pre-
ceding 14 days or pimozide); suffer from poorly
controlled epilepsy; have known allergies to sertraline,
placebo or excipients; are concurrently enrolled in an-
other investigational medicinal product (IMP) trial; are
women who are currently pregnant or planning preg-
nancy or lactating; have severe hepatic impairment;
suffer from bleeding disorders such as haemophilia,
Christmas disease or von Willebrand’s disease, or have
past medical history of bleeding gastric or duodenal ul-
cers or other significant bleeding disorders; or have had
an episode of Torsade’s de Pointes.
Fig. 1 Summary of baseline and follow-up schedule for the PANDA trial. BDI-II Beck Depression Inventory-II; CISR Clinical Interview Schedule-Revised;
EQ-5D-5L Euroqol 5D-5L; GAD-7 Generalized Anxiety Disorder-7; PHQ-9 Patient Health Questionnaire-9; SF-12 Short Form-12
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Recruitment of participants
Potential participants will be identified by GPs, who will
invite patients at a consultation or perform a database
search and mail out an invitation.
Method 1: in consultation
Given the patient’s permission for release of their contact
details, the GP will directly refer potential participants by
fax (or secure email) to the local trial centre. The re-
searcher will contact the patient to confirm eligibility for
the trial and arrange the baseline assessment visit.
Method 2: database search
GPs or practice administrative staff will carry out record
searches to identify individuals for whom the GP has re-
corded low mood or depression symptoms during previ-
ous visits (within the last 2 years) and who are not
currently on antidepressants. GPs will write to these in-
dividuals so they can consider joining the study.
The mail-out procedure will involve an initial letter
sent by the GP surgery to the identified patients, inviting
them to participate in the trial, followed by a reminder
invitation letter if there is no response, and a further
telephone call to patients who have not responded either
to the initial or reminder invitations. Patients will only
be contacted by individuals employed either directly by
the GP practice or employed by National Health Service
(NHS) organisations.
Participant eligibility confirmation
Potential participants identified either at consultation or
through a record search will receive a patient informa-
tion sheet (PIS) that provides details of the study. If the
patient agrees to be contacted by the research team, the
GP will then complete and fax an eligibility form to the
research team, confirming that the potential participant
does not suffer from any psychiatric disorders or is on
medication that would exclude them from the study. Po-
tential participants will receive an additional phone call
from a member of the research team to confirm eligibil-
ity for the trial. Provided that they do not meet any of
the exclusion criteria, patients will be invited to a base-
line assessment with a researcher either at their own
home, the general practice or University premises.
Baseline assessment
At the baseline meeting the researcher will explain the
study in detail and obtain written informed consent to
participate in the trial. Upon providing written consent,
women of child-bearing age will carry out a pregnancy
test. Participants will then undertake the following base-
line assessments: a self-administered computerised clin-
ical interview schedule (CISR) [22]; the PHQ-9 [21]; the
Beck Depression Inventory-II (BDI-II) [30]; the Short
Form-12 (SF-12) [31], the EQ-5D-5L [32]; the Generalized
Anxiety Disorder-7 (GAD-7) [33]; and emotional-
processing tasks [24, 34].
Randomisation procedure and unblinding
Upon providing written consent and undertaking the
baseline assessments, participants will be randomised to
the trial by a member of the research team, and a letter
will be sent to their GP to inform them of their patient’s
enrolment.
Participants will be randomly assigned to one of the
two treatments: (1) one × 50 mg encapsulated sertraline
for 1 week followed by two × 50 mg encapsulated sertra-
line for up to 11 weeks and then for a 2-week tapering
period or (2) identical placebo regimen. If participants
have not responded to treatment after the 6-week
follow-up assessment, the medication can be increased
to three × 50 mg encapsulated sertraline or identical pla-
cebo in consultation with the Principal Investigator (PI).
Randomisation will be conducted by PRIMENT
Clinical Trials Unit (CTU) using a remote computer-
generated code (Sealed Envelope, https://sealedenvelo
pe.com/). The randomisation will be stratified by severity
and duration of depression and by research centre, with
random block length. The pre-specified thresholds for
stratification will be the CISR total severity score at
baseline (0–11/12–19/20+) and depression duration (less
than 2 years/2 years or more). The randomisation list
will be held by Sealed Envelope. The random treatment
allocation will then be sent to the central trial pharmacy
(University Hospitals Bristol Pharmacy). Trial partici-
pants, care providers and all members of the research
team will be blinded to the trial treatment allocation.
Trial medication will be sent by the trial pharmacy to
the participant’s GP (or participant’s home in exceptional
circumstances) following the baseline and 6-week visit
and at 10 weeks (for those on the 150 mg dose).
Upon receipt of study medication, participants will be
provided with a contact card so that treating clinicians
who may be external to the study team can be unblinded
to treatment allocation in case of a clinical emergency. If
unblinding is required, a formal request by a physician
will be made to the trial pharmacy (through the 24 hour
contact number provided on the contact card) that has a
list of the participants’ treatment allocations. Study
codes should only be broken for valid medical or safety
reasons, for example in the case of a serious adverse
event (SAE) where it is necessary for the responsible
professional to know which treatment the patient is re-
ceiving before they can treat the patient. When possible,
for treating professionals outside the research team, the
unblinding request will be discussed with the investigat-
ing team (Chief Investigator (CI), local PI or delegate) so
that a formal assessment can be undertaken. If in the
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opinion of the treating physician the code must be
broken immediately, then this must be undertaken with-
out further assessment. The treating physician will man-
age the medical emergency as appropriate upon receipt
of the treatment allocation.
The CI/PI or delegate will record any breaking of the
code and reasons for doing so on the case report form
(CRF)/data collection tool and in the site file. Code
breaks will also be documented in the final study re-
ports. The CI/investigating team will notify the trial
Sponsor (University College London (UCL)) on a yearly
basis through the monitoring process. Where possible,
members of the research team should remain unblinded.
When participants have ended the study and their out-
come data have been entered into the database, they can
request to be told their treatment allocation to placebo
or active medication. This information will be provided
to their GP by the central trial pharmacy, so the partici-
pant will need to consult their GP and any further treat-
ment can be discussed during that consultation. The
trial team will remain blind to this information.
Treatment of participants
The IMP will be over-encapsulated sertraline and the
matching placebo will be an identical capsule filled with
an inert excipient. The placebo capsule will be identical
to the encapsulated sertraline in dimensions and appear-
ance, such that allocation concealment and blinding of
the trial is maintained. Participants will be asked about
adherence at all follow-up points and a pill count will be
undertaken by a member of the research team at the 6-
week and 12-week follow-up assessments. It will be re-
quested that empty packaging and unused medicines are
returned.
Follow-up assessments
The research team will aim to conduct the follow-up as-
sessments at 2, 6 and 12 weeks (see Table 1 for an over-
view of the study process). Participants will continue to
be invited to follow-up assessments unless they have
withdrawn from the trial. Research follow-up assess-
ments will take place either at the participant’s home,
the general practice or University premises. The date of
the assessments will be recorded and the analysis plan
will include measures to investigate the timing of the
follow-up appointments. Participants will continue to be
followed up even if they have stopped taking the study
medication.
The follow-up assessment schedule is as follows:
 At 2 weeks: the PHQ-9, BDI-II, SF-12, EQ-5D-5L,
GAD-7, emotional processing tasks, modified
Morisky adherence measure [35], side effects of
antidepressant medication based on a modified
version of the Toronto Side Effects scale as used
in GENPOD [36]; open-ended question about
adverse events and concomitant medication
 At 6 weeks: the PHQ-9, BDI-II, SF-12, EQ-5D-5L,
GAD-7, emotional processing tasks, modified
Morisky adherence measure and pill count, side
effects of antidepressant based on a modified
version of the Toronto Side Effects scale as used
in GENPOD, open-ended question about adverse
events and concomitant medication, health service
and other resource use
 At 12 weeks: the PHQ-9, BDI-II, SF-12, EQ-5D-5L,
GAD-7, modified Morisky adherence measure and
pill count, side effects of antidepressant based on a
modified version of the Toronto Side Effects scale
as used in GENPOD, open-ended question about
adverse events and concomitant medication, health
service and other resource use
 After 12 weeks: primary healthcare use data
(prescribed medication, primary care visits)
extracted from GP electronic health records
covering the full period of participation in the trial
Data collection tools
CISR – revised clinical interview schedule
This is a self-administered, computerised assessment of
psychiatric symptoms including depression, used at
baseline only.
PHQ-9, BDI-II, SF-12, EQ-5D-5L and GAD-7
PHQ-9, BDI-II, SF-12, EQ-5D-5L and GAD-7 are self-
administered written questionnaires.
Emotional processing tasks: memory for socially rewarding
and socially critical information task [24]
This is assessed using a computerized task administered
by a delegated member of the research team, either at
the participant’s home, the primary care surgery or the
university. At each time point, twenty likeable (e.g.
cheerful, honest) and twenty dislikeable (e.g. untidy, hos-
tile) personality characteristics are presented on a com-
puter screen in a random order (each word is presented
for 500 ms). Words are matched according to length,
ratings of usage frequency and meaningfulness, and they
differ at each time point. After each word, participants
indicate whether they would “like” or “dislike” hearing
someone describing them in this way (by pressing a key
on the keyboard). At the end of the task, participants are
asked to recall as many words as possible in 2 minutes.
This is a surprise recall task (at baseline), to test inciden-
tal memory. The number of positive and negative words
accurately recalled (hits) and the number of false re-
sponses (intrusions) are recorded.
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Table 1 Full schedule of questionnaires – table showing the questionnaires used in the PANDA study
BDI-II Beck Depression Inventory-II, CISR Clinical Interview Schedule-Revised, EQ-5D-5L Euroqol 5D-5L, GAD-7 Generalized Anxiety Disorder-7, PHQ-9 Patient Health
Questionnaire-9, SF-12 Short Form-12, GP General Practitioner
Salaminios et al. Trials  (2017) 18:496 Page 7 of 14
Emotional processing tasks: reinforcement learning task [34]
This is assessed using a computerised task administered
by a member of the research team. Each trial includes
three events: the presentation of a fractal image, the
presentation of a target and a probabilistic outcome. At
the beginning of each trial, one of four possible fractal
images is presented on a computer screen, which indi-
cates whether the best choice in a subsequent target de-
tection task is a go (pressing a key on the keyboard) or a
no-go (withholding a response to the target). The fractal
also indicates the valence of any outcome dependent on
the participant’s behaviour (reward/no reward or punish-
ment/no punishment). The meaning of fractal images
(go to win, no-go to win, go to avoid punishment, no-go
to avoid punishment) is randomised across participants,
and participants have to learn these by trial and error.
Participants are informed that the correct choice for
each fractal image is either a go (button press) or no-go
(withhold button press). Actions are required in re-
sponse to a target circle that follows the fractal image.
After a brief delay the outcome is presented (an upward
arrow indicates a win, a downwards arrow indicates a
loss and a horizontal bar indicates the absence of a win
or a loss). On go-to-win trials, a button press is
rewarded; on go-to-avoid-punishment trials, a button
press avoids punishment; in no-go-to-win trials, with-
holding a button press is rewarded and in no-go-to-
avoid-losing trials, withholding a button press avoids
punishment. The task consists of 240 trials in total (60
trials per condition). The participant can win between
£1 and £10. These data can be analysed using computa-
tional models [34].
Outcome measures
Primary outcomes
1. Depressive symptoms measured using the PHQ-9 at
6 weeks as a continuous outcome
Secondary outcomes
1. Depressive symptoms with the PHQ-9 at 2 and
12 weeks
2. BDI-II as an alternative measure of depressive
symptoms at all follow-up points
3. Anxiety symptoms measured using the GAD-7 at all
follow-up points
4. Quality of life assessed using the EQ-5D-5L and SF-12
5. NHS costs associated with care, time off work and
additional care and personal costs
6. Emotional processing tasks scores at baseline and 2
and 6 weeks
Withdrawal from the trial
Participants may withdraw at any time but once dosing
has occurred, every attempt should be made to continue
assessments to ensure the safety of the individual con-
cerned. Specific reasons for a participant withdrawing
from the trial may be:
 Voluntary discontinuation by the individual, who is
at any time free to discontinue his/her participation
in the study, without prejudice to further treatment
 Risk to patients as judged by the investigator
 Severe non-compliance with the protocol as judged
by the local site PI
 Incorrectly randomised individuals
 Adverse events
Any person who withdraws will always be asked about
the reason(s) for withdrawal and the presence of any ad-
verse events. If possible, they will be seen and assessed
by the local site primary investigator or delegate. Ad-
verse events will be followed up and trial discontinuation
will be documented in the appropriate CRF pages. If
possible, participants who discontinue the study medica-
tion before completion should undergo the assessments
and procedures scheduled for the follow-up visits. Once
participants have stopped their trial medication, they
may not resume trial treatment.
A patient may withdraw from the follow-up visits or
they may withdraw their consent for any data collected to
be used. Patients will be encouraged to allow data that
have been collected before withdrawal to be used in the
analyses. However, if consent to use data is also with-
drawn, then these data will be discarded. Patients with-
drawing from the study will revert to the care of their GP.
Trial medication
Packaging, labelling and dispensing
Medication packs will be labelled in accordance with ap-
plicable regulations and the Medicines and Healthcare
products Regulatory Agency (MHRA) approvals. Each
medication pack will have a medicine ID number, ran-
domly generated to ensure sertraline and placebo medi-
cine packs are indistinguishable (e.g. avoid all placebo
packs being assigned an odd number) and thus maintain
allocation concealment. This random number will be
generated by the CTU and provided to the manufacturer
who will use it as a unique identifier for the IMP pack-
ages and for the randomisation and code-break services.
The manufacturer will ship labelled and numbered
packages to the pharmacy where the trial medication
will be stored under controlled conditions. Storage will
be secure, and there will be a delegation log for access,
for which the pharmacy will take responsibility. The
pharmacy will dispense individual patient packs and
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oversee the packaging and posting of those packs. After
randomisation patient packs containing 6 weeks’ supply
(90 capsules) of the trial medication will be posted by re-
corded delivery to the participant’s GP surgery or, in ex-
ceptional circumstances, their homes. After the 6-week
assessment has been completed a further 6 weeks’ medi-
cation, including sufficient medication for the tapering
period (90 capsules) will be posted by recorded delivery.
All deliveries will be logged to ensure drug accountabil-
ity. The trial medication will be shipped and stored in
line with manufacturer’s stability data.
Full IMP accountability records will be maintained in
the trial, and receipt, dispensing, distribution, return and
destruction records will be maintained at the dispensing
pharmacy. When the IMP arrives at the general practice
it will be kept in a secure locked cabinet until collected
by the participant. The receipt and collection of the IMP
will be logged by the research team.
Concomitant medication
Sertraline should not be administered concomitantly
with monoamine oxidase (MAO) inhibitors or within 2
weeks after discontinuation of MAO inhibitor therapy.
Likewise at least 2 weeks should elapse before patients
treated with sertraline are treated with MAO inhibitors.
Participants in this study will not be treated with MAO
inhibitors. Sertraline should not be administered con-
comitantly with pimozide.
Co-administration with other serotonergic active
substances (L-tryptophan, triptans, tramadol, linezolid,
lithium and St. John’s Wort – Hypericum perforatum
– preparations) may lead to an incidence of
serotonin-associated effects and participants will be
advised not to take any of these medications for the
duration of the trial.
Sertraline may increase the sedating properties of
benzodiazepines and other sedatives (notably most anti-
psychotics, antihistamine H1 antagonists, opioids). Par-
ticipants will be advised that caution should be exercised
when these medicinal products are prescribed together
with sertraline and they should be alert to the possibility
of over-sedation.
Sertraline may increase the central nervous system
(CNS) depressant effect of alcohol. Participants will
therefore be advised to be cautious in their intake of al-
cohol while taking sertraline.
Co-administration of sertraline 200 mg daily with war-
farin can result in a small increase in prothrombin time. If
the participant is taking warfarin the GP will be asked to
monitor prothrombin time when sertraline therapy is ini-
tiated or stopped and provide the results to the local PI.
The risk of bleeding may be increased when medicines
acting on platelet function (e.g. nonsteroidal anti-
inflammatory drugs (NSAIDs), acetylsalicylic acid and
ticlopidine) or other medicines that might increase
bleeding risk are concomitantly administered with SSRIs,
including sertraline. The PI will decide whether the par-
ticipant should be included in the study if they are also
taking any NSAIDs or other medicines that might in-
crease bleeding risk.
Participants will be allowed to take hypnotic medica-
tion along with the trial medication. The GP will con-
firm other medication that the participant is taking in
order to assess contraindications to sertraline before the
baseline assessment. Participants will be asked about any
concomitant medication at all follow-up points.
Adverse events (AEs)
All AEs (untoward medical occurrences in a patient or
clinical trial participant administered a medicinal product,
which do not necessarily have a causal relationship with
this treatment) will be recorded by a structured assess-
ment in the follow-up assessments at 2, 6 and 12 weeks. If
a participant consults the GP with a known AE it will be
recorded in the medical notes only but not communicated
to the PI unless specifically requested. This will include
any AEs that occur during the tapering period after the
12-week assessment. As this trial is a trial of a licensed
medication with a well-established safety profile that is
used within its licensed indication, AEs will not be re-
corded in the CRF apart from those AEs of special interest
included in the follow-up assessments.
Patients will be asked about serious adverse events
(SAEs) at each visit using open-ended questions. All SAEs
will be recorded in the CRF and the Sponsor’s SAE log.
The SAE log will be reportable to the Sponsor once a year.
The PI or delegate at trial sites will inform the CI of
any SAEs. The CI or an appropriate member of staff will
complete the SAE form and will send it to the Sponsor
via email within 24 hours of becoming aware of the
event. The CI/PI may contact the patient’s GP, depend-
ing upon the nature of the SAE, to obtain more informa-
tion on the adverse event. All suspected unexpected
serious adverse reactions (SUSARs) must be notified to
the Sponsor within 24 hours. The Sponsor will notify
the main Research Ethics Committee (REC) and the
MHRA of all SUSARs. SUSARs that are fatal or life-
threatening must be notified to the MHRA and REC
within 7 days after the Sponsor has learned of them.
Other SUSARs must be reported to the REC and MHRA
within 15 days after the Sponsor has learned of them.
Statistical analysis
We will follow the Consolidated Standards of Reporting
Trials (CONSORT) guidelines [37] in reporting and ana-
lysing our data. We will create a flow chart that will pro-
vide the number of potential participants who were
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screened, eligible, randomised and followed up at each
time point.
Our primary outcome will be the PHQ-9 at 6
weeks. We will use a mixed-effects generalised linear
modelling framework as it is appropriate for repeated
measures data [38, 39]. The analyses will include ad-
justments for baseline PHQ-9 score and the stratifica-
tion variables (severity in three categories, duration in
two categories and centre). As we want to estimate
the relationship between the CISR depression score
and treatment, we will include this in the model (be-
ing aware of the possibility of collinearity) and will
also use robust multivariate techniques.
We will carry out further analyses to assess the sen-
sitivity of any results to the modelling assumptions
and the covariance structure. This will be relevant to
both the primary and secondary analyses. For the pri-
mary analysis we will carry out the analysis without
the CISR depression severity measure in order to
examine the robustness of the findings. We will
examine the extent of individual heterogeneity in the
longitudinal outcomes, if any. We will also examine
interactions between baseline severity and treatment
outcome within the model.
Other approaches to investigate include modelling
the data with a linear regression model with different
link functions in which log PHQ-9 is used for the
outcome and baseline, and using a linear regression
model with and without an interaction term. We will
also carry out a sensitivity analysis by adjusting for
any variables that are not balanced at baseline
(themselves ascertained through descriptive statistics
only). The duration of the depressive episode is mea-
sured before randomisation using the CISR assess-
ment at baseline. The CISR includes a question about
duration after each symptom section. After the de-
pressive symptoms section the question asks about
the following categories: less than 2 weeks, between 2
weeks and 6 months, between 6 months and 1 year,
between 1 and 2 years, between 2 and 5 years, be-
tween 5 and 10 years and more than 10 years. Dur-
ation will be investigated as an additional parameter
in the model used for the primary analysis.
Missing data: we will carry out sensitivity analyses to
investigate the possible impact of missing data. The two
main approaches will be to adjust for baseline variables
associated with missing outcome data and also to use
multiple imputation. We will make strenuous efforts to
reduce the amount of missing data and in our power cal-
culations have estimated that there will be up to 10%
missing data at 6 weeks. In a similar previous trial
(GENPOD) we obtained 91% follow up at 6 weeks [36].
Secondary analyses: the following secondary analyses
will be conducted adjusting for the baseline measure of
the outcome variable, stratification and minimisation
variables:
– PHQ-9 score as a continuous outcome at 2, 6 and
12 weeks in a repeated measures analysis
– PHQ-9 score as a binary outcome where remission
is defined as scoring < 10 on the PHQ-9 at 2, 6 and
12 weeks in a repeated measures analysis
– BDI-II score as a continuous outcome at 2, 6 and 12
weeks in a repeated measures analysis
– BDI-II score as a binary outcome (BDI-II <10) at 2,
6 and 12 weeks in a repeated measures analysis
– GAD-7 scores as a continuous outcome at 2, 6 and
12 weeks in a repeated measures analysis
– SF-12 physical and mental component scores at 2, 6
and 12 weeks in a repeated measures analysis
– Self-reported global improvement at 2, 6 and 12
weeks in a repeated measures analysis
– A mediation analysis to investigate whether scores
on the emotional processing tasks at 2 weeks
mediate a therapeutic effect on PHQ-9 at 6 and 12
weeks [40]
The choice of regression model will depend upon the
outcome. Distributional assumptions appropriate for
positive continuous outcomes will be investigated in-
cluding those that model proportionate reduction of
symptoms. The SF-12 is usually modelled using linear
regression as this seems a good fit to the data. Logistic
regression will be the used for the analysis of binary out-
come data.
Economic analysis
The economic evaluation will estimate costs from the
NHS and social services perspective based on a review
of medical notes and from responses to service and
resource-use questionnaires. Unit costs will be obtained
from published national sources where possible [41–43].
Cost will be expressed in pounds sterling, valued in the
most recent available unit costs, adjusted for inflation
where necessary. The EQ-5D-5L collected at baseline
and 2, 6 and 12 weeks will be used to calculate quality
adjusted life years (QALYs). EQ-5D-5L assesses quality
of life in five domains and an index score is derived
using a UK value set [44].
We will estimate the cost-effectiveness (cost per QALY)
of sertraline at 12 weeks post randomisation. Diffe-
rences between arms in costs and QALYs, and their
confidence intervals, will be calculated using linear re-
gression. We will also estimate (again with linear re-
gression) the incremental net monetary benefit (INMB)
[45] and associated confidence intervals, based on
standard NICE cost-effectiveness thresholds [46]. We
will estimate cost-effectiveness acceptability curves to
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depict the probability that sertraline is cost-effective at
different values of this threshold. We will use net bene-
fit regression [47] to explore the interaction between
baseline symptom severity and duration and the cost-
effectiveness of sertraline. If necessary, we will estimate
cost-effectiveness models under multiple imputation of
data, using imputation models as for the analysis of the
primary trial outcome.
We will also conduct a descriptive, non-inferential
“cost-consequences” analysis [48]. This will compare the
primary and secondary outcomes of the trial, and the
QALY outcomes described above, with costs to the
NHS, social services and individual participants.
Justification of sample size
We propose to use a model that will estimate a propor-
tionate reduction in PHQ-9 score as the treatment ef-
fect, so we can analyse the data without using an
interaction term. The results from previous meta-
analyses suggest that the effect size of SSRIs versus pla-
cebo is about an 11% reduction in the Hamilton Rating
Scale for Depression (HAM-D) score [49]. In the
Fournier meta-analysis [12], the reduction is about 17%
(personal communication, Jay Fournier). We have there-
fore taken the 11% estimate as the more conservative
option in order to inform our power calculation. Our
best estimate of the minimal clinically important differ-
ence (MCID) from the PANDA cohort study is that this
corresponds to a 14 percentage points (95% CI 10 to 17
percentage points) reduction in score on the PHQ-9
(unpublished results but see [50] for a description of the
approach). Therefore giving the power for effect sizes of
11 and 14 percentage points is reasonable and conserva-
tive in the light of the confidence limits and the previous
results from the systematic review.
An 11 percentage-point difference corresponds to a
difference in proportions of 0.89 and this is −0.117 on
the natural logarithm scale. A 14% difference corre-
sponds to 0.86 and −0.15 on the natural logarithm scale.
We have estimated the SD of the logarithm of PHQ-9
scores using existing data from the PANDA cohort study
in a Poisson regression in which the follow-up PHQ-9
scores are the outcome and the baseline scores are an
offset variable. This led to an estimate of SD of 0.32 −
0.34 for the log PHQ9. Given the uncertainty in estimat-
ing SDs we have also included estimates assuming an SD
of 0.4. We have assumed a normal distribution as this
will be a good approximation to the Poisson distribution
for the sample sizes involved.
Table 2 gives our estimates of sample size assuming a
significance level of 5% (two sided) and power of 90%.
Given the uncertainties surrounding many of the assump-
tions, we chose to recruit a sample of 547 participants.
Data handling and quality assurance
The trial sponsor is UCL and it takes primary responsi-
bility for ensuring that the design of the study meets ap-
propriate standards and that arrangements are in place
to ensure appropriate conduct and reporting. A moni-
toring plan has been agreed with the Sponsor. The trial
will be run in accordance with Good Clinical Practice
(GCP) and current regulatory guidance. All data at the
site will be handled according to the Data Protection
Act 1998 and UCL Information Security Policy and
Trust Information Governance Policy. The investigators
have full access to all the data and are under no restric-
tions in their use of the data. We are open to approaches
from bona fide researchers to have access to the data
providing this is consistent with our ethics and regula-
tory approvals.
Publication policy
The funder, National Institute for Health Research
(NIHR), is informed of the publications before they are
submitted to journals. The co-applicants have agreed a
publication policy. Publications will conform to the
International Committee of International Journal Editors
(ICMJE) guidelines for reporting and authorship.
Ethics, regulatory approvals and reporting
The Sponsor will ensure that the trial protocol, patient
information sheet, consent form, GP letter and submit-
ted supporting documents have been approved by the
appropriate regulatory body (MHRA in the UK) and the
main research ethics committee, prior to any patient
recruitment. The protocol and all agreed substantial
protocol amendments were documented and submitted
for ethical and regulatory approval prior to implementa-
tion. Ethical approval was obtained from the National
Research Ethics Service committee, East of England -
Cambridge South (ref: 13/EE/0418). Clinical trial authori-
zation was given by the MHRA. The trial Sponsor is UCL.
The trial has been registered with EudraCT Number
2013-003440-22, ISRCTN84544741. The protocol adheres
to the Standard Protocol Items: Recommendations for
Intervention Trials (SPIRIT). The SPIRIT Checklist is
available as an Additional file 1.
Table 2 The sample size estimates for the PANDA trial with a
variety of assumptions
Percentage
point reduction
Natural log of
reduction
SD
estimate
Total
sample size
Allowing for
10% attrition
11 −0.117 0.34 366 407
14 −0.150 0.34 216 240
11 −0.117 0.4 492 547
14 −0.150 0.4 300 333
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It is the responsibility of the CI/PI or designee at each
site to ensure that all subsequent amendments gain the
necessary approval. This does not affect the individual
clinician’s responsibility to take immediate action if
thought necessary to protect the health and interest of
individual patients.
The trial investigators and institutions will permit
trial-related monitoring, audits, REC review, and regula-
tory inspections, providing direct access to source data/
documents. Trial participants are informed of this dur-
ing the informed consent discussion.
Within 90 days after the end of the trial, the CI/Sponsor
will ensure that the main REC and the MHRA are notified
that the trial has finished. If the trial is terminated prema-
turely, those reports will be made within 15 days after the
end of the trial. The CI will supply the Sponsor with a
summary report of the clinical trial, which will then be
submitted to the MHRA and main REC within 1 year after
the end of the trial.
There is a Trial Steering Committee chaired by Professor
Carolyn Chew-Graham of Keele University. The other in-
dependent members are Professor Ian Anderson, Dr Evan
Kontopantelis, Professor Anne Rogers and Mr Paul
Lanham. The Independent Data Monitoring Committee is
chaired by Prof Chris Williams of Glasgow University. The
other members are Professor Richard Byng and Dr Obi
Ukoumunne.
Insurance
The UCL holds insurance against claims from participants
for injury caused by their participation in the clinical trial.
Participants may be able to claim compensation if they
can prove that UCL has been negligent.
Discussion
PANDA is a pragmatic primary-care trial with broad in-
clusion criteria, aiming to address important aspects of
current clinical practice. Trial participants will be re-
cruited from a wide range of primary care settings across
the four study sites, based in urban, rural, affluent and
deprived areas across the UK, thus minimizing selection
bias. Given that the main treatment effect of sertraline
occurs within 6 weeks, our primary outcome will be
measured at the 6-week follow-up assessment. We have
included a follow-up assessment at 2 weeks to obtain an
early account of potential adverse events and the first
signs of clinical response and at 12 weeks to obtain evi-
dence of any sustained benefits of antidepressant treat-
ment. Self-report measures will be used to assess clinical
outcome in order to eliminate potential observer bias.
As common adverse effects of sertraline may lead to in-
advertent unblinding, we will ask trial participants at
each follow-up period to indicate to which treatment
arm they believe they have been allocated.
Given the increasing rates of antidepressant prescrip-
tion across the UK and the clinical challenge associated
with accurately assessing depressive symptoms during
short consultation appointments, there is a need to iden-
tify which patients presenting to primary care with de-
pression are more likely to benefit from a course of
antidepressants. Our study will use a simple, self-
administered, computerised assessment to establish the
severity and duration of depressive symptoms and inves-
tigate any association with a clinically significant re-
sponse to sertraline. The evidence from the trial will be
used to inform primary-care prescribing practice by
identifying which patients are more likely to benefit
from antidepressants and using assessments that have
the potential to be used in primary care.
Trial status
The trial began recruiting participants in January 2015
and will be ongoing until August 2017. At the time of
writing (June 2017), 161 general practices have been ac-
tively involved in PANDA and 573 participants have
been randomised into the study. It is expected that data
collection will be completed in November 2017.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
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